Project Tango
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Opportunity
A debt-free, privately owned pharmaceutical company established in 1987, with $70M revenue, 28% EBITDA, 58 branded generic RX products focused on oncology, hematology, rheumatology, orphan drugs, and rare diseases, multiple EU-GMP manufacturing sites, distribution in 40 countries, and an owner open to 100% acquisition.
Company Profile
Established in 1987, this privately owned pharmaceutical company (single
owner) has built a robust portfolio of 58 generic RX and MAH products. It operates multiple certified manufacturing sites for solid, oncology, and sterile liquid forms, with a strong medical R&D background and a track record as a pioneer and distributor in novel therapies.
Therapeutic Focus
Specialized RX portfolio in high value areas: Oncology, Radiology, Rheumatology, Hematology, Orphan
Drugs, and Rare Diseases. Strong domestic presence via dedicated salesforce, complemented
by worldwide distribution in 40 countries.
Financial Performance
Proven financial stability with no debt and consistent profitability. Generates $70 million in revenue with 28% EBITDA margin, driven by self-built branded generic RX products.
Investment Opportunity
Seeking: The owner is open to a 100% acquisition, offering a strategic buyer an established, debt-free platform with strong manufacturing capabilities, niche expertise in specialty and orphan therapies, and significant international distribution footprint for further scaling and growth.